SOPHiA GENETICS SA
SOPH Healthcare Health Information Services
SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow SOPH
SOPHiA GENETICS SA (SOPH) P/E ratio
SOPHiA GENETICS SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MDRX Veradigm Inc. compare | n/m |
| SOPH SOPHiA GENETICS SA | n/m |
| EVH Evolent Health, Inc compare | n/m |
| WEAV Weave Communications, Inc. compare | n/m |
| CTEV Claritev Corporation compare | n/m |
| CARL Carlsmed, Inc. compare | n/m |
| HSTM HealthStream, Inc. compare | 46.0× |
| PHR Phreesia, Inc. compare | 64.4× |
| NRC National Research Corporation compare | 80.6× |
| Health Information Services industry median | 39.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)